ClinicalTrials.gg
RecruitingNCT07743671Updated Nov 13, 2026

A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

A Phase 3 interventional study of Engasertib and Placebo in Hereditary Hemorrhagic Telangiectasia, sponsored by Vaderis Therapeutics AG. Recruiting at 17 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Vaderis Therapeutics AG · Phase 3, Interventional, and Treatment

Updated Nov 13, 2026First sites in 8 new countriesStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States — 5 open to participants now, 8 under way, 1 of them phase 3. Telangiectasia, Hereditary Hemorrhagic · United States.

Planned enrollment
Largest of 20
240 · median 27
Started
2026
with 2 others
Phase 3
Only one
of the 29
Registered
29th of 29
by date
Lead sponsor
2 of 29
Vaderis Therapeutics AG

Among the 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States, this one has the largest planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 3, and was the 29th registered.

Telangiectasia, Hereditary Hemorrhagic

106 studies on the registry are indexed under Telangiectasia, Hereditary Hemorrhagic; 24 are open to participants now.

Browse Telangiectasia, Hereditary Hemorrhagic studies →

Open to participants now

5 of the 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Telangiectasia, Hereditary Hemorrhagic studies recruiting now, 14 (82%) set no upper age limit and 2 (12%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with moderate to severe HHT.

03

Conditions studied

  • Hereditary Hemorrhagic Telangiectasia

Keywords

  • Hereditary Hemorrhagic Telangiectasia
  • HHT
  • Engasertib
  • VAD044
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants are ≥18 years of age at the Screening Visit.
  2. Participants have a definite diagnosis of HHT by the Curaçao criteria, defined as spontaneous and recurrent epistaxis and having at least 2 of the following criteria:

    1. Multiple telangiectases at characteristic sites: lips, oral cavity, fingers, or nose;
    2. Visceral lesions: gastrointestinal telangiectasia and/or pulmonary, hepatic, cerebral, or spinal arteriovenous malformations (AVMs); or
    3. A first degree relative with HHT according to these criteria.
  3. Participants must have an ESS >4 at screening, and, in the judgement of the Investigator, participants are expected to have regular epistaxis that typically lasts for several minutes. This criterion is assessed at screening only and does not require reconfirmation prior to randomization on Day 1.
  4. Participants have anemia OR in the prior 6 months have received a parenteral infusion of at least 250 mg of iron OR in the prior 6 months have received a red cell or whole blood transfusion.

Exclusion criteria

Exclusion Criteria:

  1. History or current diagnosis of (ECG) abnormalities.
  2. History of significant or uncontrolled skin disorders per Investigator's judgement.
  3. Local ablative (eg, cauterization) or surgical procedures on nasal telangiectases \<6 weeks before the Screening Visit.
  4. Use of drugs with anti-angiogenic properties, including, but not limited to, bevacizumab, pazopanib, thalidomide, lenalidomide, pomalidomide, tacrolimus, sirolimus, or selective estrogen response modulators (tamoxifen, raloxifene, or bazedoxifene) \< 6 weeks before the Screening Visit.
  5. Use of oral tranexamic or epsilon-aminocaproic acid unless they are on a stable dose for at least 4 weeks before the Screening Visit, which will need to be continued during the entire duration of the double-blind Treatment Period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Engasertib 40 mg

    Participants will receive engasertib as an oral capsule QD for 28 weeks.

    Drug: Engasertib

  • Placebo comparator
    Placebo

    Participants will receive matching placebo as an oral capsule QD for 28 weeks.

    Drug: Placebo

Interventions

  • Engasertib will be administered as oral capsules.

    Also known as: VAD044

  • DrugPlacebo

    Placebo will be administered as oral capsules.

06

What researchers measure

Primary outcomes

  1. Total Number of Epistaxis Events Through Week 28

    Time frame: Day 1 through Week 28

Secondary outcomes

  1. Absolute Change from Baseline in Total Duration of Epistaxis at Week 28

    Time frame: Baseline and Week 28

  2. Absolute Change from Baseline in Epistaxis Severity Score (ESS) at Week 28

    Time frame: Baseline and Week 28

  3. Absolute Change from Baseline in the Nasal Outcome Score for Epistaxis in HHT (NOSE HHT) Score at Week 28

    Time frame: Baseline and Week 28

  4. Absolute Change in Red Blood Cell (RBC) Unit Equivalents (RUEs) Received at Week 28

    Time frame: Baseline and Week 28

  5. Patient Global Impression of Change (PGIC) Nosebleeds Question at Week 28

    Time frame: Week 28

  6. HHT-specific Quality of Life (HHT-QoL) Score at Week 28

    Time frame: Week 28

  7. Absolute Change from Baseline in the Intensity-adjusted Duration of Epistaxis per Month at Week 28

    Time frame: Baseline and Week 28

07

Study locations

17 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Jun 2028, 19 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 4, 2026
StartActual
Nov 2, 2026was Sep 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added — first sites in Belgium, France, Germany, Hungary, Italy and 3 more
All 8 countries

Belgium, France, Germany, Hungary, Italy, Netherlands, Spain, United Kingdom

Show 13 added (2 United States, 2 Belgium, 2 France, 2 United Kingdom, 1 Germany, 1 Hungary, 1 Italy, 1 Netherlands, 1 Spain)
  • University of Florida · Gainesville, United States
  • University of Utah Hospital · Salt Lake City, United States
  • University Hospital Ghent (UZ Gent) · Ghent, Belgium
  • University Hospitals Leuven (UZ Leuven) · Leuven, Belgium
  • CHU Angers · Angers, France
  • CHU Bordeaux - St-Andre Hospital · Bordeaux, France
  • Saarland University-Diagnostic & Interventional Radiology Campus Homburg Building 50.1 · Homburg, Germany
  • Debreceni Egyetem Klinikal Központ · Debrecen, Hungary
  • ASST - Ospedale Maggiore di Crema · Crema, Italy
  • St. Antonius Ziekenhuis · Utrecht, Netherlands
  • Hospital Universitario Ramon y Cajal · Madrid, Spain
  • Castle Hill Hospital · Cottingham, United Kingdom
  • Clinical Research Centre (CRC) · Dundee, United Kingdom
Nov 13, 2026
Start date
Sep 2026→Nov 2, 2026 (actual)
Nov 13, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedPatient Global Impression of Change (PGIC) Nosebleeds Sub-scoreQuestion at Week 28Time frame: Week 28
Nov 13, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • The University of Chicago Medical Center (UCMC) · Chicago, United StatesContact •••4043→•••4043
  • Innovative Hematology, Inc., · Indianapolis, United StatesContact •••0011→•••0011
  • Mayo Clinic · Rochester, United StatesContact •••2158→•••2158
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    13 sites added — first sites in Belgium, France, Germany, Hungary, Italy and 3 more
    All 8 countries

    Belgium, France, Germany, Hungary, Italy, Netherlands, Spain, United Kingdom

    Show 13 added (2 United States, 2 Belgium, 2 France, 2 United Kingdom, 1 Germany, 1 Hungary, 1 Italy, 1 Netherlands, 1 Spain)
    • University of Florida · Gainesville, United States
    • University of Utah Hospital · Salt Lake City, United States
    • University Hospital Ghent (UZ Gent) · Ghent, Belgium
    • University Hospitals Leuven (UZ Leuven) · Leuven, Belgium
    • CHU Angers · Angers, France
    • CHU Bordeaux - St-Andre Hospital · Bordeaux, France
    • Saarland University-Diagnostic & Interventional Radiology Campus Homburg Building 50.1 · Homburg, Germany
    • Debreceni Egyetem Klinikal Központ · Debrecen, Hungary
    • ASST - Ospedale Maggiore di Crema · Crema, Italy
    • St. Antonius Ziekenhuis · Utrecht, Netherlands
    • Hospital Universitario Ramon y Cajal · Madrid, Spain
    • Castle Hill Hospital · Cottingham, United Kingdom
    • Clinical Research Centre (CRC) · Dundee, United Kingdom
    Start date Sep 2026→Nov 2, 2026 (now actual)
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedPatient Global Impression of Change (PGIC) Nosebleeds Sub-scoreQuestion at Week 28Time frame: Week 28
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • The University of Chicago Medical Center (UCMC) · Chicago, United StatesContact •••4043→•••4043
    • Innovative Hematology, Inc., · Indianapolis, United StatesContact •••0011→•••0011
    • Mayo Clinic · Rochester, United StatesContact •••2158→•••2158
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07743671
Lead sponsor
Vaderis Therapeutics AG
Responsible party
Sponsor
First posted
Aug 4, 2026
Start date
Nov 2, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Vaderis Therapeutics AG
Contact
info@vaderis.com
844-823-3747 ext. +1

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Engasertib

Start the discussion